Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study

Abstract

Dermatological chemotherapy side effects are frequent after treatment of women's cancers and have a major impact on quality of life as assessed by HRQL. Counseling of patients with women's cancers and the profile of side effects of chemotherapeutic agents should be considered before considering an adjuvant or palliative chemotherapy regimen.

Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study

“…The high frequency and negative impact on QoL of dermatological toxicities in this population, as described in this and previous studies (Gandhi et al, 2010;Hackbarth et al, 2008;Ra et al, 2013;Sibaud et al, 2016) highlight the need for optimised supportive oncodermatology to be widely accessible to patients both during and after treatment. In addition, the period immediately after treatment has been identified as a time of increased psychosocial distress among survivors (Montazeri et al, 2008;Paraskevi, 2012).…”

“…Compared with other common adverse events after chemotherapy, such as gastrointestinal disorders, fatigue and decreased immunity, dAEs frequently cause higher levels of concern among cancer survivors after the end of treatment (Gandhi et al, 2010;Hackbarth et al, 2008;Rosen et al, 2013). Here, we reported a very high prevalence (81%) of grade-1 or 2 xerosis at inclusion in our total study population.…”

“…Finally, the efficacy of hydrotherapy was evaluated only in the short term; further studies are required to determine if the benefits of this treatment are maintained in the longer term, 6 months or a T A B L E 3 Prevalence of dermatological AEs by severity (NCI CTCAE version 4.02 grade) in the study population at the beginning of treatment (V2) year after treatment. However, it should be noted that dermatological toxicities stand for the main immediate chemotherapy-induced adverse events, which are often unanticipated by patients (Gandhi et al, 2010;Hackbarth et al, 2008), and are mainly responsible for QoL impairment (Gandhi et al, 2010;Hackbarth et al, 2008;Ra et al, 2013;Sibaud et al, 2016). Besides, our results were confirmed by a large randomised clinical trial (PACThe study) in 251 patients, which investigated hydrotherapy as supportive treatment in women in breast cancer remission, shortly after chemotherapy completion (Kwiatkowski et al, 2013).…”

“…Several studies conducted in patients with gynaecologic cancers have identified dAEs as one of the most significant toxicities limiting quality of life (QoL) and as leading factors impairing functional, emotional, physical and social well-being in cancer patients (Gandhi, Oishi, Zubal, & Lacouture, 2010;Hackbarth, Haas, Fotopoulou, Lichtenegger, & Sehouli, 2008;Ra et al, 2013;Sibaud et al, 2016), especially because they often persist long after completion of chemotherapy (Gandhi et al, 2010).…”

Efeitos colaterais cutâneos de quimioterapia com taxanos: O ponto de vista do dermatologista

“…They pre sent a simi lar mode of action but a dis tinct pro fi le regar ding cuta neous adver se reac tions. 1 With the pur po se of making der ma to lo gists more fami liar with this kind of reac tion, which will beco me more fre quent with grea ter uti li za tion of TX, we report below 4 cases that were fol lo wed in a derma to logy offi ce.…”